Tyr589
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr589  -  FLT3 (human)

Site Information
TGSSDNEyFyVDFRE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 448189

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 2 ) , mass spectrometry ( 4 ) , mutation of modification site ( 1 , 3 , 5 , 6 ) , phospho-antibody ( 1 , 6 ) , phosphopeptide mapping ( 2 ) , western blotting ( 1 )
Disease tissue studied:
leukemia ( 1 ) , acute myelogenous leukemia ( 1 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
FLT3 (human) ( 2 )
Treatments:
FL ( 1 , 2 , 6 )

Downstream Regulation
Effects of modification on FLT3:
enzymatic activity, inhibited ( 2 ) , molecular association, regulation ( 2 ) , phosphorylation ( 3 , 5 )
Effects of modification on biological processes:
cell growth, altered ( 3 )
Induce interaction with:
Src (human) ( 2 )

References 

1

Razumovskaya E, et al. (2009) Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation. Exp Hematol 37, 979-89
19477218   Curated Info

2

Heiss E, et al. (2006) Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood 108, 1542-50
16684964   Curated Info

3

Rocnik JL, et al. (2006) Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD. Blood 108, 1339-45
16627759   Curated Info

4

Moritz A (2004) CST Curation Set: 623; Year: 2004; Biosample1/Treatment/Isotope: cell line, NCI-H1650/EGF/L, Biosample2/Treatment/Isotope: cell line, NCI-H1650/EGF/Iressa/H; Disease: non-small cell lung cancer; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Kiyoi H, et al. (2002) Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21, 2555-63
11971190   Curated Info

6

Kiyoi H, et al. (1998) Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12, 1333-7
9737679   Curated Info